← Leaderboards
Catherine Simpson
Johns Hopkins University
$1,574,335
Attributed
$1,574,335
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $637.3K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,574,335 · 4
By mechanism
K23$882,900 · 1
R01$514,484 · 1
R03$122,813 · 1
F32$54,138 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Roger A Johns$24,853,899
- Viswanathan Natarajan$24,234,784
- Brian Scott Caffo$5,113,824
- Larissa A Shimoda$18,862,133
- John Huetsch$808,976
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypePathway InteractionsLungTherapeutic TargetBiologicalPulmonary Arterial HypertensionSerumImproved OutcomeClinical DataProspectiveSamplingNew Therapeutic TargetEndothelial CellsMetabolicNovel MarkerEnzymesMortalityNewly DiagnosedSclerodermaComplexAnimal ModelLongitudinal CohortInsightBiological Markers
Grant awards (8)
The role of kynurenine pathway metabolism in pulmonary arterial hypertension$514,484
R01 · FY2025 · HL · contact PI
Lipidomics of Pulmonary Vascular Disease$122,813
R03 · FY2025 · HL · contact PI
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension$176,580
K23 · FY2024 · HL · contact PI
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension$176,580
K23 · FY2023 · HL · contact PI
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension$176,580
K23 · FY2022 · HL · contact PI
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension$176,580
K23 · FY2021 · HL · contact PI
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertension$176,580
K23 · FY2020 · HL · contact PI
Uric Acid and its Genetic Regulators as Biomarkers of Pulmonary Arterial Hypertension in Scleroderma$54,138
F32 · FY2019 · HL · contact PI